✓
Open
27 Jul 2021
✓
Close
29 Jul 2021
3
Allotment
—
✓
Listing
Fri, Aug 6, 2021
Price Band
₹695 to ₹720
Issue Size
2,10,22,222 shares (agg. up to ₹1,514 Cr)
Lot Size
20 Shares
Listing Date
Fri, Aug 6, 2021
Latest GMP
₹82
Est. Gain
11.39%
✦ AI Insight
GMP Trend
06-08-2021₹82Est. ₹802+11.39%
05-08-2021₹90Est. ₹810+12.5%
04-08-2021₹83Est. ₹803+11.53%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 31.02x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|
| Assets | 1,997.08 | 1,725.60 | 1,475.40 |
| Total Income | 1,885.98 | 1,549.30 | 886.87 |
| Profit After Tax | 351.58 | 313.10 | 195.59 |
| EBITDA | 591.89 | 483.95 | 248.16 |
| NET Worth | 752.75 | 401.69 | 88.13 |
| Reserves and Surplus | 750.79 | 399.73 | 86.17 |
| Total Borrowing | 0.00 | 0.02 | 0.02 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd. | Mainboard | ₹6,479.55 Cr | ₹1500 | null | ₹1,819.55 | +21.30% | ₹2,449.00 (-3.29%) |
| Walpar Nutritions Ltd. | SME | ₹6.60 Cr | ₹55 | null | ₹57.00 | +3.64% | ₹34.50 (+0.00%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 | 800.00 |
| 2 | Funding the capital expenditure requirements | 152.76 |
| 3 | General corporate purposes | 57.68 |
About Glenmark Life Sciences IPO
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies. Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020. Competitive strengths Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management. Export products in Europe, Latin America, North America, Japan, and the rest of the world. Strong relationship with leading global generic companies. Proven track record of strong financial performance. High-quality p
Contact Details
Glenmark Life Sciences Ltd. AddressPlot No.170-172, Chandramouli Industrial EstateMohol BazarpethSolapur, Maharashtra, 413213+91 2189 234456/ +91 2189complianceofficer@glenmarklifesciences.comVisit Website